November 15, 2019

PRODUCT SUPPLY UPDATE - ONCOLOGY

PrFLUDARABINE PHOSPHATE FOR INJECTION, 25 mg/mL, DIN 02283859

Dear Healthcare Provider,

Fludarabine phosphate for injection is indicated for second line treatment in patients with chronic lymphocytic leukemia (CLL) and low-grade non-Hodgkin’s lymphoma (Lg-NHL) who have failed other conventional therapies (Product Monograph, Teva Canada Limited, March 1, 2016).

CURRENT SUPPLY STATUS

<table>
<thead>
<tr>
<th>Product</th>
<th>Current Supply</th>
<th>Allocation Filter in Place</th>
<th>Alternate Sources</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 mL single use vial</td>
<td>Teva Warehouse: 15 weeks</td>
<td>Direct orders are individually assessed</td>
<td>Injectable: None Oral Tablets: PrFludara®</td>
</tr>
<tr>
<td></td>
<td>NOW AVAILABLE</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

PrFludara® (fludarabine phosphate tablets 10 mg) is a registered trademark exclusively licensed to Genzyme Corporation (marketed by sanofi-aventis Canada Inc.)

Please check the Health Canada Drug Shortages Website for updates on this product.

HOW TO ORDER – DIRECT FROM TEVA

- Until supply stabilizes we will self-distribute
- Please email the following information to Customer.Service@tevacanada.com
  1. Your current inventory on hand
  2. Purchase order

Thank you for your understanding and continued support.

Sincerely,
Hospital Division